GnRH (Gonadotropin-Releasing Hormone)

Endometriosis Treatment

LHRH agonists create a hypoestrogenic state that causes regression of endometriotic implants. Henzl et al. (1988) demonstrated that nafarelin nasal spray was effective for endometriosis pain relief. Treatment is typically limited to 6 months due to bone density concerns from prolonged estrogen deprivation, though add-back therapy (low-dose estrogen/progestin) extends the treatment window.

Central Precocious Puberty

LHRH agonists are first-line therapy for central precocious puberty (CPP), suppressing premature activation of the HPG axis to preserve adult height potential and allow age-appropriate psychosocial development. Carel et al. (2009) reviewed long-term outcomes, confirming safety and efficacy of treatment for up to several years with recovery of normal puberty upon discontinuation.

IVF Downregulation Protocols

In assisted reproduction, LHRH agonists are used in the "long protocol" to achieve pituitary downregulation before controlled ovarian stimulation. Starting in the mid-luteal phase of the preceding cycle, daily LHRH agonist administration suppresses endogenous gonadotropin release, preventing premature LH surges during stimulation. The "short/flare" protocol exploits the initial gonadotropin surge to supplement exogenous FSH stimulation Daya (2000).

Prostate Cancer and Androgen Deprivation

The landmark work by Schally et al. (1980) and Labrie et al. (1980) demonstrated that LHRH agonist administration could achieve medical castration equivalent to orchiectomy in men with advanced prostate cancer. This transformed prostate cancer management by providing a reversible, non-surgical alternative. Huggins & Hodges (1941) had established the androgen dependence of prostate cancer decades earlier, but LHRH agonists made androgen deprivation practical and widely accessible.

Pulsatile GnRH and Differential Gonadotropin Regulation

The seminal work by Knobil (1980) demonstrated that pulsatile GnRH delivery is essential for sustained gonadotropin secretion in primates, while continuous infusion leads to suppression. Subsequent studies established that pulse frequency differentially regulates LH versus FSH through distinct transcription factor activation: high-frequency pulses activate Egr-1, which drives LH-beta transcription, while low-frequency pulses activate AP-1, favoring FSH-beta expression Kaiser et al. (1997).

GnRH Receptor Pharmacology

The GnRHR was cloned and characterized in the early 1990s, revealing its unique structural features among GPCRs. Millar et al. (2004) provided a comprehensive review of GnRHR signaling, demonstrating the receptor's coupling to multiple downstream cascades including MAPK/ERK, JNK, and p38 pathways beyond the canonical Gq/11-PLC axis. The absence of the C-terminal tail was shown to confer resistance to rapid desensitization, explaining the requirement for continuous agonist exposure to achieve receptor downregulation.

GnRH in Puberty and Development

GnRH neuron activity is quiescent during childhood and reactivates at puberty onset. Seminara et al. (2003) and de Roux et al. (2003) identified loss-of-function mutations in KISS1R (GPR54) as a cause of hypogonadotropic hypogonadism, establishing the kisspeptin-GnRH pathway as the critical gatekeeper for puberty. GnRH neuron migration from the olfactory placode during embryonic development, when disrupted, causes Kallmann syndrome — the combination of hypogonadotropic hypogonadism and anosmia.

Agonist vs Antagonist Therapeutics

GnRH agonists (leuprolide, goserelin, triptorelin) exploit the paradoxical suppression mechanism: initial flare followed by sustained downregulation of the GnRH receptor, achieving medical castration within 2-4 weeks. GnRH antagonists (cetrorelix, ganirelix, degarelix) block the receptor immediately without flare, providing faster onset of suppression. Conn & Crowley (1994) reviewed the clinical development of both drug classes.

Reproductive endocrinology and diagnostics

Gonadotropin-releasing hormone (as gonadorelin) is an established diagnostic and therapeutic agent. Given as a single IV bolus it drives pituitary LH/FSH release and forms the basis of the GnRH stimulation test used to evaluate the hypothalamic-pituitary-gonadal axis and delayed puberty. Delivered in a pulsatile fashion via pump it reproduces physiologic hypothalamic rhythm and is a highly effective, physiologic ovulation-induction therapy in functional hypothalamic amenorrhea, as well as a fertility treatment in male hypogonadotropic hypogonadism. Pulsatile GnRH offers predominantly monofollicular ovulation with lower risks of multiple pregnancy and ovarian hyperstimulation than injectable gonadotropins.

• The GnRH stimulation test is a gold-standard probe of pituitary-gonadal axis integrity.
• Pulsatile GnRH restores ovulation with high live birth rates and mostly monofollicular development in functional hypothalamic amenorrhea.
• Pulsatile GnRH induces virilization, testicular growth and spermatogenesis in male hypogonadotropic hypogonadism.
• Compared with gonadotropins, pulsatile GnRH carries lower multiple-pregnancy and ovarian hyperstimulation risk.